{
  "trial_id": "NCT01458652",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Thrice a week for more then",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Receiving HDF patients who had been treated for > 3 months",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Non-smoking",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Informed Consent",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "No significant change of medication",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Malignancy",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Active infection",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Congestive heart failure (CHF)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "History of Gastrointestinal Disease(Active peptic ulcer, severe constipation or severe GI dysmotility)",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "Patient has been treated with corticosteroid and cyclophosphamides for Wegener's granulomatosis for 4 months. His Birmingham Vasculitis Activity Score (BVAS) is above 4.",
  "_meta": {
    "topic_id": "54",
    "trial_id": "NCT01458652",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}